APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastric Mucosal Protective Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gastric Mucosal Protective Drug Market Outlook and Growth Opportunities 2026

23 December 2025190 pages

Choose your research edition.

Industry ResearchGastric Mucosal Protective Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastric Mucosal Protective Drug Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Gastric Mucosal Protective Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastric Mucosal Protective Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastric Mucosal Protective Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Gastric Mucosal Protective Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gastric Mucosal Protective Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gastric Mucosal Protective Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gastric Mucosal Protective Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gastric Mucosal Protective Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gastric Mucosal Protective Drug market include Zhejaing Yuanlijian, Eisai Co., Teva, LIVZON, Guangdong Huanan Pharma, Bayer, AbbVie, Viatris and Otsuka Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Gastric Mucosal Protective Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gastric Mucosal Protective Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gastric Mucosal Protective Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Gastric Mucosal Protective Drug market.

Gastric Mucosal Protective Drug Segment by Company

Zhejaing Yuanlijian

Eisai Co.

Teva

LIVZON

Guangdong Huanan Pharma

Bayer

AbbVie

Viatris

Otsuka Pharmaceutical

Nostrum Pharmaceuticals

Endo International

Astellas Pharma

Amneal Pharmaceuticals

Gastric Mucosal Protective Drug Segment by Type

Rebamipide

Sucralfate

Bismuth Potassium Citrate

Other

Gastric Mucosal Protective Drug Segment by Application

Hospital

Retail Pharmacy

Other

Gastric Mucosal Protective Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Gastric Mucosal Protective Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Gastric Mucosal Protective Drug key companies, revenue, market share, and recent developments.

3. To split the Gastric Mucosal Protective Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Gastric Mucosal Protective Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gastric Mucosal Protective Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Gastric Mucosal Protective Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastric Mucosal Protective Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastric Mucosal Protective Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastric Mucosal Protective Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gastric Mucosal Protective Drug industry.

Chapter 3: Detailed analysis of Gastric Mucosal Protective Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Gastric Mucosal Protective Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Gastric Mucosal Protective Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gastric Mucosal Protective Drug Industry Trends Table 2. Gastric Mucosal Protective Drug Industry Drivers Table 3. Gastric Mucosal Protective Drug Industry Opportunities and Challenges Table 4. Gastric Mucosal Protective Drug Industry Restraints Table 5. Global Gastric Mucosal Protective Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gastric Mucosal Protective Drug Revenue Share by Company (2021-2026) Table 7. Global Gastric Mucosal Protective Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Gastric Mucosal Protective Drug Key Company Manufacturing Base & Headquarters Table 9. Global Gastric Mucosal Protective Drug Company, Product Type & Application Table 10. Global Gastric Mucosal Protective Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Gastric Mucosal Protective Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Rebamipide Table 15. Significant Companies of Sucralfate Table 16. Significant Companies of Bismuth Potassium Citrate Table 17. Significant Companies of Other Table 18. Global Gastric Mucosal Protective Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Gastric Mucosal Protective Drug Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Gastric Mucosal Protective Drug Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Gastric Mucosal Protective Drug Sales Value Share by Type (2021-2026) Table 22. Global Gastric Mucosal Protective Drug Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Retail Pharmacy Table 25. Significant Companies of Other Table 26. Global Gastric Mucosal Protective Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Gastric Mucosal Protective Drug Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Gastric Mucosal Protective Drug Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Gastric Mucosal Protective Drug Sales Value Share by Application (2021-2026) Table 30. Global Gastric Mucosal Protective Drug Sales Value Share by Application (2027-2032) Table 31. Global Gastric Mucosal Protective Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Gastric Mucosal Protective Drug Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Gastric Mucosal Protective Drug Sales Value Share by Region (2021-2026) Table 34. Global Gastric Mucosal Protective Drug Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Gastric Mucosal Protective Drug Sales Value Share by Region (2027-2032) Table 36. Global Gastric Mucosal Protective Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Gastric Mucosal Protective Drug Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Gastric Mucosal Protective Drug Sales Value Market Share by Country (2021-2026) Table 39. Global Gastric Mucosal Protective Drug Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Gastric Mucosal Protective Drug Sales Value Market Share by Country (2027-2032) Table 41. Zhejaing Yuanlijian Company Information Table 42. Zhejaing Yuanlijian Business Overview Table 43. Zhejaing Yuanlijian Gastric Mucosal Protective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Zhejaing Yuanlijian Gastric Mucosal Protective Drug Product Portfolio Table 45. Zhejaing Yuanlijian Recent Development Table 46. Eisai Co. Company Information Table 47. Eisai Co. Business Overview Table 48. Eisai Co. Gastric Mucosal Protective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Eisai Co. Gastric Mucosal Protective Drug Product Portfolio Table 50. Eisai Co. Recent Development Table 51. Teva Company Information Table 52. Teva Business Overview Table 53. Teva Gastric Mucosal Protective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Teva Gastric Mucosal Protective Drug Product Portfolio Table 55. Teva Recent Development Table 56. LIVZON Company Information Table 57. LIVZON Business Overview Table 58. LIVZON Gastric Mucosal Protective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. LIVZON Gastric Mucosal Protective Drug Product Portfolio Table 60. LIVZON Recent Development Table 61. Guangdong Huanan Pharma Company Information Table 62. Guangdong Huanan Pharma Business Overview Table 63. Guangdong Huanan Pharma Gastric Mucosal Protective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Guangdong Huanan Pharma Gastric Mucosal Protective Drug Product Portfolio Table 65. Guangdong Huanan Pharma Recent Development Table 66. Bayer Company Information Table 67. Bayer Business Overview Table 68. Bayer Gastric Mucosal Protective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Bayer Gastric Mucosal Protective Drug Product Portfolio Table 70. Bayer Recent Development Table 71. AbbVie Company Information Table 72. AbbVie Business Overview Table 73. AbbVie Gastric Mucosal Protective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. AbbVie Gastric Mucosal Protective Drug Product Portfolio Table 75. AbbVie Recent Development Table 76. Viatris Company Information Table 77. Viatris Business Overview Table 78. Viatris Gastric Mucosal Protective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Viatris Gastric Mucosal Protective Drug Product Portfolio Table 80. Viatris Recent Development Table 81. Otsuka Pharmaceutical Company Information Table 82. Otsuka Pharmaceutical Business Overview Table 83. Otsuka Pharmaceutical Gastric Mucosal Protective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Otsuka Pharmaceutical Gastric Mucosal Protective Drug Product Portfolio Table 85. Otsuka Pharmaceutical Recent Development Table 86. Nostrum Pharmaceuticals Company Information Table 87. Nostrum Pharmaceuticals Business Overview Table 88. Nostrum Pharmaceuticals Gastric Mucosal Protective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Nostrum Pharmaceuticals Gastric Mucosal Protective Drug Product Portfolio Table 90. Nostrum Pharmaceuticals Recent Development Table 91. Endo International Company Information Table 92. Endo International Business Overview Table 93. Endo International Gastric Mucosal Protective Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Endo International Gastric Mucosal Protective Drug Product Portfolio Table 95. Endo International Recent Development Table 96. Astellas Pharma Company Information Table 97. Astellas Pharma Business Overview Table 98. Astellas Pharma Gastric Mucosal Protective Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Astellas Pharma Gastric Mucosal Protective Drug Product Portfolio Table 100. Astellas Pharma Recent Development Table 101. Amneal Pharmaceuticals Company Information Table 102. Amneal Pharmaceuticals Business Overview Table 103. Amneal Pharmaceuticals Gastric Mucosal Protective Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Amneal Pharmaceuticals Gastric Mucosal Protective Drug Product Portfolio Table 105. Amneal Pharmaceuticals Recent Development Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Gastric Mucosal Protective Drug Product Image Figure 2. Global Gastric Mucosal Protective Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastric Mucosal Protective Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Gastric Mucosal Protective Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Rebamipide Image Figure 8. Sucralfate Image Figure 9. Bismuth Potassium Citrate Image Figure 10. Other Image Figure 11. Global Gastric Mucosal Protective Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Gastric Mucosal Protective Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Gastric Mucosal Protective Drug Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Retail Pharmacy Image Figure 16. Other Image Figure 17. Global Gastric Mucosal Protective Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Gastric Mucosal Protective Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Gastric Mucosal Protective Drug Sales Value Share by Application (2021-2032) Figure 20. Global Gastric Mucosal Protective Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Gastric Mucosal Protective Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Gastric Mucosal Protective Drug Sales Value (2021-2032) & (US$ Million) Figure 23. North America Gastric Mucosal Protective Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Gastric Mucosal Protective Drug Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Gastric Mucosal Protective Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Gastric Mucosal Protective Drug Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Gastric Mucosal Protective Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Gastric Mucosal Protective Drug Sales Value (2021-2032) & (US$ Million) Figure 29. South America Gastric Mucosal Protective Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Gastric Mucosal Protective Drug Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Gastric Mucosal Protective Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Rebamipide
  • Sucralfate
  • Bismuth Potassium Citrate
  • Other
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Zhejaing Yuanlijian
  • Eisai Co.
  • Teva
  • LIVZON
  • Guangdong Huanan Pharma
  • Bayer
  • AbbVie
  • Viatris
  • Otsuka Pharmaceutical
  • Nostrum Pharmaceuticals
  • Endo International
  • Astellas Pharma
  • Amneal Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Gastric Mucosal Protective Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Gastric Mucosal Protective Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Gastric Mucosal Protective Drug Market Dynamics
  1. 2.1 Gastric Mucosal Protective Drug Industry Trends
  2. 2.2 Gastric Mucosal Protective Drug Industry Drivers
  3. 2.3 Gastric Mucosal Protective Drug Industry Opportunities and Challenges
  4. 2.4 Gastric Mucosal Protective Drug Industry Restraints
3 Gastric Mucosal Protective Drug Market by Company
  1. 3.1 Global Gastric Mucosal Protective Drug Company Revenue Ranking in 2025
  2. 3.2 Global Gastric Mucosal Protective Drug Revenue by Company (2021-2026)
  3. 3.3 Global Gastric Mucosal Protective Drug Company Ranking (2024-2026)
  4. 3.4 Global Gastric Mucosal Protective Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Gastric Mucosal Protective Drug Company Product Type and Application
  6. 3.6 Global Gastric Mucosal Protective Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Gastric Mucosal Protective Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Gastric Mucosal Protective Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Gastric Mucosal Protective Drug Market by Type
  1. 4.1 Gastric Mucosal Protective Drug Type Introduction
  2. 4.1.1 Rebamipide
  3. 4.1.2 Sucralfate
  4. 4.1.3 Bismuth Potassium Citrate
  5. 4.1.4 Other
  6. 4.2 Global Gastric Mucosal Protective Drug Sales Value by Type
  7. 4.2.1 Global Gastric Mucosal Protective Drug Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Gastric Mucosal Protective Drug Sales Value by Type (2021-2032)
  9. 4.2.3 Global Gastric Mucosal Protective Drug Sales Value Share by Type (2021-2032)
5 Gastric Mucosal Protective Drug Market by Application
  1. 5.1 Gastric Mucosal Protective Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Gastric Mucosal Protective Drug Sales Value by Application
  6. 5.2.1 Global Gastric Mucosal Protective Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Gastric Mucosal Protective Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Gastric Mucosal Protective Drug Sales Value Share by Application (2021-2032)
6 Gastric Mucosal Protective Drug Regional Value Analysis
  1. 6.1 Global Gastric Mucosal Protective Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gastric Mucosal Protective Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Gastric Mucosal Protective Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Gastric Mucosal Protective Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Gastric Mucosal Protective Drug Sales Value (2021-2032)
  7. 6.3.2 North America Gastric Mucosal Protective Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Gastric Mucosal Protective Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Gastric Mucosal Protective Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Gastric Mucosal Protective Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Gastric Mucosal Protective Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Gastric Mucosal Protective Drug Sales Value (2021-2032)
  16. 6.6.2 South America Gastric Mucosal Protective Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Gastric Mucosal Protective Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Gastric Mucosal Protective Drug Sales Value Share by Country, 2025 VS 2032
7 Gastric Mucosal Protective Drug Country-level Value Analysis
  1. 7.1 Global Gastric Mucosal Protective Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gastric Mucosal Protective Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Gastric Mucosal Protective Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Gastric Mucosal Protective Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Gastric Mucosal Protective Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Gastric Mucosal Protective Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Gastric Mucosal Protective Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhejaing Yuanlijian
  2. 8.1.1 Zhejaing Yuanlijian Company Information
  3. 8.1.2 Zhejaing Yuanlijian Business Overview
  4. 8.1.3 Zhejaing Yuanlijian Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Zhejaing Yuanlijian Gastric Mucosal Protective Drug Product Portfolio
  6. 8.1.5 Zhejaing Yuanlijian Recent Developments
  7. 8.2 Eisai Co.
  8. 8.2.1 Eisai Co. Company Information
  9. 8.2.2 Eisai Co. Business Overview
  10. 8.2.3 Eisai Co. Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eisai Co. Gastric Mucosal Protective Drug Product Portfolio
  12. 8.2.5 Eisai Co. Recent Developments
  13. 8.3 Teva
  14. 8.3.1 Teva Company Information
  15. 8.3.2 Teva Business Overview
  16. 8.3.3 Teva Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Teva Gastric Mucosal Protective Drug Product Portfolio
  18. 8.3.5 Teva Recent Developments
  19. 8.4 LIVZON
  20. 8.4.1 LIVZON Company Information
  21. 8.4.2 LIVZON Business Overview
  22. 8.4.3 LIVZON Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 LIVZON Gastric Mucosal Protective Drug Product Portfolio
  24. 8.4.5 LIVZON Recent Developments
  25. 8.5 Guangdong Huanan Pharma
  26. 8.5.1 Guangdong Huanan Pharma Company Information
  27. 8.5.2 Guangdong Huanan Pharma Business Overview
  28. 8.5.3 Guangdong Huanan Pharma Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Guangdong Huanan Pharma Gastric Mucosal Protective Drug Product Portfolio
  30. 8.5.5 Guangdong Huanan Pharma Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Gastric Mucosal Protective Drug Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 AbbVie
  38. 8.7.1 AbbVie Company Information
  39. 8.7.2 AbbVie Business Overview
  40. 8.7.3 AbbVie Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AbbVie Gastric Mucosal Protective Drug Product Portfolio
  42. 8.7.5 AbbVie Recent Developments
  43. 8.8 Viatris
  44. 8.8.1 Viatris Company Information
  45. 8.8.2 Viatris Business Overview
  46. 8.8.3 Viatris Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Viatris Gastric Mucosal Protective Drug Product Portfolio
  48. 8.8.5 Viatris Recent Developments
  49. 8.9 Otsuka Pharmaceutical
  50. 8.9.1 Otsuka Pharmaceutical Company Information
  51. 8.9.2 Otsuka Pharmaceutical Business Overview
  52. 8.9.3 Otsuka Pharmaceutical Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Otsuka Pharmaceutical Gastric Mucosal Protective Drug Product Portfolio
  54. 8.9.5 Otsuka Pharmaceutical Recent Developments
  55. 8.10 Nostrum Pharmaceuticals
  56. 8.10.1 Nostrum Pharmaceuticals Company Information
  57. 8.10.2 Nostrum Pharmaceuticals Business Overview
  58. 8.10.3 Nostrum Pharmaceuticals Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Nostrum Pharmaceuticals Gastric Mucosal Protective Drug Product Portfolio
  60. 8.10.5 Nostrum Pharmaceuticals Recent Developments
  61. 8.11 Endo International
  62. 8.11.1 Endo International Company Information
  63. 8.11.2 Endo International Business Overview
  64. 8.11.3 Endo International Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Endo International Gastric Mucosal Protective Drug Product Portfolio
  66. 8.11.5 Endo International Recent Developments
  67. 8.12 Astellas Pharma
  68. 8.12.1 Astellas Pharma Company Information
  69. 8.12.2 Astellas Pharma Business Overview
  70. 8.12.3 Astellas Pharma Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Astellas Pharma Gastric Mucosal Protective Drug Product Portfolio
  72. 8.12.5 Astellas Pharma Recent Developments
  73. 8.13 Amneal Pharmaceuticals
  74. 8.13.1 Amneal Pharmaceuticals Company Information
  75. 8.13.2 Amneal Pharmaceuticals Business Overview
  76. 8.13.3 Amneal Pharmaceuticals Gastric Mucosal Protective Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Amneal Pharmaceuticals Gastric Mucosal Protective Drug Product Portfolio
  78. 8.13.5 Amneal Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst